Purple Biotech
PPBT
10 hedge funds and large institutions have $157K invested in Purple Biotech in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 6 → 10 (+4)
0% more ownership
Funds ownership: 0% → 0% (+0%)
30% less capital invested
Capital invested by funds: $225K → $157K (-$68K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$80.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$47.8K |
| 3 |
VF
Virtu Financial
New York
|
+$27.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$22.6K |
| 5 |
BAM
Bruderman Asset Management
Locust Valley,
New York
|
+$2.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Menta Capital
San Francisco,
California
|
-$40.3K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$10.1K |
| 3 |
Morgan Stanley
New York
|
-$2.52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $63K | +$80.5K | +32 | +200% |
|
|
2
Citadel Advisors
Miami,
Florida
| $26K | +$47.8K | +19 | New |
|
|
MC
3
Menta Capital
San Francisco,
California
| $16K | -$40.3K | -16 | -57% |
|
|
VF
4
Virtu Financial
New York
| $15K | +$27.7K | +11 | New |
|
|
SM
5
Sabby Management
Miami Beach,
Florida
| $13K | -$10.1K | -4 | -29% |
|
|
TSS
6
Two Sigma Securities
New York
| $12K | +$22.6K | +9 | New |
|
7
Wells Fargo
San Francisco,
California
| $7K | – | – | – |
|
|
8
Morgan Stanley
New York
| $2K | -$2.52K | -1 | -50% |
|
9
UBS Group
Zurich,
Switzerland
| $2K | +$2.52K | +1 | +100% |
|
|
BAM
10
Bruderman Asset Management
Locust Valley,
New York
| $1K | +$2.52K | +1 | New |
|
PPBT Hedge Fund Activity: Q4 2018 in Review
10 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2018, worth a combined $157K — down 30% from $225K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PPBT positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $80.5K. The largest seller was Menta Capital, cutting an estimated $40.3K.
- 10 institutional investors held Purple Biotech (PPBT) as of Q4 2018, up from 6 in Q3 2018.
- Funds reported $157K of Purple Biotech stock for Q4 2018, down 30% quarter-over-quarter.
- 4 funds opened new Purple Biotech positions in Q4 2018 and 0 closed out, a net change of +4 holders.
- The largest Purple Biotech buyer in Q4 2018 was Susquehanna International Group, an estimated $80.5K added.
- The largest Purple Biotech seller in Q4 2018 was Menta Capital, an estimated $40.3K sold.
Based on aggregated 13F filings for Q4 2018.